Study protocol of a randomized controlled trial of fistula vs. graft arteriovenous vascular access in older adults with end-stage kidney disease on hemodialysis: the AV access trial

Mariana Murea,Ali I. Gardezi,Mathew P. Goldman,Caitlin W. Hicks,Timmy Lee,John P. Middleton,Roman Shingarev,Tushar J. Vachharajani,Karen Woo,Lama M. Abdelnour,Kyla M. Bennett,Duvuru Geetha,Lee Kirksey,Kevin W Southerland,Carlton J. Young,William M. Brown,Judy Bahnson,Haiying Chen,Michael Allon
DOI: https://doi.org/10.1186/s12882-023-03086-5
2023-02-26
BMC Nephrology
Abstract:Treatment of end-stage kidney disease (ESKD) with hemodialysis requires surgical creation of an arteriovenous (AV) vascular access—fistula (AVF) or graft (AVG)—to avoid (or limit) the use of a central venous catheter (CVC). AVFs have long been considered the first-line vascular access option, with AVGs as second best. Recent studies have suggested that, in older adults, AVGs may be a better strategy than AVFs. Lacking evidence from well-powered randomized clinical trials, integration of these results into clinical decision making is challenging. The main objective of the AV Access Study is to compare, between the two types of AV access, clinical outcomes that are important to patients, physicians, and policy makers.
urology & nephrology
What problem does this paper attempt to address?